SAGE-718

SAGE-718 is an experimental drug developed by Sage Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts. It is currently under investigation for its potential use in the treatment of various central nervous system (CNS) disorders, including Huntington's disease, Parkinson's disease, and Alzheimer's disease.

Mechanism of Action

SAGE-718 is a positive allosteric modulator of the NMDA receptor, a type of ionotropic glutamate receptor in the brain. By enhancing the function of the NMDA receptor, SAGE-718 may help to improve cognitive function and reduce symptoms in patients with CNS disorders.

Clinical Trials

As of 2021, SAGE-718 is in Phase 2 clinical trials for the treatment of cognitive impairment associated with Huntington's disease. Preliminary results from these trials have shown promise, with patients demonstrating improved cognitive function after treatment with SAGE-718.

Potential Applications

In addition to its potential use in treating Huntington's disease, SAGE-718 is also being investigated for its potential use in treating other CNS disorders, including Parkinson's disease and Alzheimer's disease. Further research is needed to determine the efficacy and safety of SAGE-718 in these patient populations.

See Also

• Sage Therapeutics
• NMDA receptor
• Huntington's disease
• Parkinson's disease
• Alzheimer's disease

References

SAGE-718 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski